Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This post-marketing surveillance (PMS) study was conducted to monitor the usage of axitinib (Inlyta) in clinical practice of Korean patients with advanced renal cell carcinoma (RCC) with disease progression during or after a prior systemic therapy in real world. Materials and Methods In this multicenter, observational study, patients indicated for oral axitinib 5 mg twice daily as second-line therapy for advanced RCC were followed up under routine clinical practices, and their safety and effectiveness outcomes were collected. Results Between 2012 and 2021, 125 patients were enrolled, and data from 111 patients were analyzed. Median age was 65 years (range, 30 to 84 years), 81% was male, and 110 (99%) had clear cell RCC. The median daily dose of axitinib was 10 mg (range, 4.36 to 15.95 mg) with a median administration period of 5.6 months (range, 15 to 750 days). Eighty-three percentage of patients experienced any grade of adverse events, 71% of which were related to study treatment, including diarrhea (36%), hypertension (21%), stomatitis (17%), decreased appetite (14%), palmar-plantar erythrodysesthesia syndrome (12%), and asthenia (11%). Most adverse events were generally well tolerated and manageable, with 13% of grade ≥ 3. Axitinib dose reduction was required in 20% of the adverse events and discontinuation in 8%. Median progression-free survival was 12.4 months (95% confidence interval [CI], 9.6 to 18.9). Objective responses were observed in 30% of patients (95% CI, 21 to 39) with 4% of complete response and 26% of partial response. Conclusion No new safety signal was found in the present PMS study of Korean RCC patients. Axitinib showed consistent outcomes in terms of effectiveness and safety confirming that the drug is a valid option for second-line therapy in patients with advanced RCC in a real-world setting.
Abstract
Purpose This post-marketing surveillance (PMS) study was conducted to monitor the usage of axitinib (Inlyta) in clinical practice of Korean patients with advanced renal cell carcinoma (RCC) with disease progression during or after a prior systemic therapy in real world. Materials and Methods In this multicenter, observational study, patients indicated for oral axitinib 5 mg twice daily as second-line therapy for advanced RCC were followed up under routine clinical practices, and their safety and effectiveness outcomes were collected. Results Between 2012 and 2021, 125 patients were enrolled, and data from 111 patients were analyzed. Median age was 65 years (range, 30 to 84 years), 81% was male, and 110 (99%) had clear cell RCC. The median daily dose of axitinib was 10 mg (range, 4.36 to 15.95 mg) with a median administration period of 5.6 months (range, 15 to 750 days). Eighty-three percentage of patients experienced any grade of adverse events, 71% of which were related to study treatment, including diarrhea (36%), hypertension (21%), stomatitis (17%), decreased appetite (14%), palmar-plantar erythrodysesthesia syndrome (12%), and asthenia (11%). Most adverse events were generally well tolerated and manageable, with 13% of grade ≥ 3. Axitinib dose reduction was required in 20% of the adverse events and discontinuation in 8%. Median progression-free survival was 12.4 months (95% confidence interval [CI], 9.6 to 18.9). Objective responses were observed in 30% of patients (95% CI, 21 to 39) with 4% of complete response and 26% of partial response. Conclusion No new safety signal was found in the present PMS study of Korean RCC patients. Axitinib showed consistent outcomes in terms of effectiveness and safety confirming that the drug is a valid option for second-line therapy in patients with advanced RCC in a real-world setting.
참고문헌 (13)
- 홍세리, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018", Cancer Research and Treatment, 53(2), pp.301~315 (2021), 대한암학회[DOI]
- Padala SA, "Epidemiology of renal cell carcinoma", World J Oncol, 11, pp.79~87 (2020)
- Motzer RJ, "Sunitinib versus interferon alfa in metastatic renal-cell carcinoma", N Engl J Med, 356, pp.115~124 (2007)
- Sternberg CN, "Pazopanib in locally advanced or metastatic renal cell carcinoma : results of a randomized phase III trial", J Clin Oncol, 28, pp.1061~1068 (2010)
- Rini BI, "Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma(AXIS) : a randomised phase 3 trial", Lancet, 378, pp.1931~1939 (2011)
- Sonpavde G, "Axitinib for renal cell carcinoma", Expert Opin Investig Drugs, 17, pp.741~748 (2008)
- Motzer RJ, "Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma : overall survival analysis and updated results from a randomised phase 3 trial", Lancet Oncol, 14, pp.552~562 (2013)
- Bracarda S, "Is axitinib still a valid option for mRCC in the second-line setting? Prognostic factor analyses from the AXIS trial", Clin Genitourin Cancer, 17, pp.e689~703 (2019)
- Qin S, "Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma : results from a randomized registrational study", Onco Targets Ther, 8, pp.1363~1373 (2015)
- Barata PC, "Treatment of renal cell carcinoma : current status and future directions", CA Cancer J Clin, 67, pp.507~524 (2017)
- Pinto A, "Clinical factors associated with long-term benefit in patients with metastatic renal cell carcinoma treated with axitinib : real-world AXILONG study", Clin Genitourin Cancer, 20, pp.25~34 (2022)
- Auvray M, "Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma", Eur J Cancer, 108, pp.33~40 (2019)
- Shah AY, "Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors", Eur J Cancer, 114, pp.67~75 (2019)